20191-74-6

Basic information

• Product Name: 2-Ethyl-5-nitrobenzenamine ,98%
• Synonyms: 2-Ethyl-5-nitrobenzenamine ,98%;2-ethyl-5-nitroaniline;BenzenaMine, 2-ethyl-5-nitro-;2-Ethyl-5-nitro-phenylaMine;4-Nitro-2-amino-1-ethylbenzene;2-Ethyl-5-nitroaniline 2-Ethyl-5-nitrobenzenamine;2-Ethyl-5-nitrobenzenamine 98%
• CAS NO: 20191-74-6
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.179
• Mol File: 20191-74-6.mol

Chemical Properties

• Melting Point: 63-64℃ (methanol )
• Boiling Point: 335.339 °C at 760 mmHg
• Flash Point: 156.607 °C
• Appearance: /
• Density: 1.218±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.000121mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.25±0.10(Predicted)
• CAS DataBase Reference: 2-Ethyl-5-nitrobenzenamine ,98%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Ethyl-5-nitrobenzenamine ,98%(20191-74-6)
• EPA Substance Registry System: 2-Ethyl-5-nitrobenzenamine ,98%(20191-74-6)

Safety Data

• Statements: 20/21/22
• Safety Statements: 36/37
• Hazardous Substances Data: 20191-74-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H10N2O2/c1-2-6-3-4-7(10(11)12)5-8(6)9/h3-5H,2,9H2,1H3

Upstream product

• 33098-65-6 2-acetamido-1-ethylbenzene 
• 578-54-1 ortho-ethylaniline 
• 1204-29-1 1-ethyl-2,4-dinitrobenzene 
• 612-22-6 2-nitro(ethylbenzene) 

Downstream Products

• 90005-90-6 2-ethyl-5-nitro-phenol 
• 42782-54-7 3-Chloro-4-ethylnitrobenzene 
• 133053-77-7 2,4-dibromo-6-ethyl-3-nitroaniline 
• 52121-34-3 2-bromo-1-ethyl-4-nitrobenzene 
• 263270-83-3 3-chloromethyl-N-(2-ethyl-5-nitrophenyl)benzamide 
• 263270-88-8 N-(5-amino-2-ethylphenyl)-3-(4-methylpiperazin-1-ylmethyl)benzamide 
• 91880-38-5 N-(2-ethyl-5-nitrophenyl)acetamide 
• 444731-75-3 N-(2-chloropyrimidin-4-yl)-N-methyl-2,3-dimethyl-2H-indazole-6-amine 
• 635702-64-6 pazopanib hydrochloride 
• 444731-52-6 pazopanib 
• 444731-72-0 2,3-dimethyl-6-amino-2H-indazole 
• 1376676-65-1 N,2,3-trimethyl-2H-indazole-6-amine 
• 635702-60-2 2,3-dimethyl-2H-indazole-6-amine hydrochloride 
• 1620059-29-1 N²-(3-chloro-4-fluorophenyl)-N⁴-(2,3-dimethyl-2H-indazol-6-yl)-N⁴-methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine 

Relevant articles and documents

Preparation method of pazopanib intermediate

The invention provides a preparation method of a pazopanib key intermediate 2,3-dimethyl-N-(2-chloropyrimidin-4-yl)-N-methyl-2H-indazole-6-amine. The method comprises the following steps: by taking 6-halogenated-2,3-dimethyl-2H-indazole as a raw material, conducting reacting to obtain N,2,3-trimethyl-2H-indazole-6-amine; and further carrying out a reaction to obtain the 2,3-dimethyl-N-(2-chloropyrimidin-4-yl)-N-methyl-2H-indazole-6-amine. The method has the advantages of short synthesis route, accessible raw materials, low cost, mild reaction conditions, high safety and high yield, and is suitable for industrial mass production.

Hydrochloric acid [...] of the method for the preparation of intermediates

The invention discloses a preparation method of an intermediate (2,3-dimethyl-N-(2-chloropyrimidine-4-base)-N-methyl-2H-indazole-6-amine) of pazopanib hydrochloride as shown in a formula I. The preparation method comprises the step of performing nucleophilic substitution reaction on a compound III and 2,4-dichloropyrimidine in an organic solvent under the action of alkali, wherein the reaction temperature is 0-160 DEG C. According to the preparation method disclosed by the invention, raw materials are low in price and easy to obtain, and the preparation method is convenient to operate, high in product yield and suitable for industrial large-scale production.

2,3-dimethyl-6-urea -2H-indazoles and its preparation method and application

The invention discloses a 2, 3-dimethyl-6-urea-2H-indazole compound shown by the following general formula (I), medicinal salt or a solvent compound thereof, wherein Ar is substituted or unsubstituted phenyl or aromatic matrix. The invention also discloses a preparation method and application of the compound. The compound can regulate signal transduction of tyrosine kinase, inhibit bad cellular proliferation, and particularly has obvious curative effect for tumors.

Discovery and synthesis of N2,N4-substitued- cycloalkyl[d]pyrimidine-2,4-diamine analogs: The first examples of small-molecular FGFR-1 activator

A series of novel, cycloalkyl-modified pazopanib analogs 2 and 3 were designed and synthesized. Their kinase modulatory effects on FGFR-1, VEGFR-2, PDGFR-β, and c-KIT were evaluated by the caliper mobility shift assay. Introduction of cycloalkyl into the pyrimidine linker of pazopanib almost abolished the four kinases inhibitory potency of compounds 2 and 3, but surprisingly, resulted in good activation effects on FGFR-1. Compounds 3d and 3g showed double-digit, nanomolar, selective activation effects on FGFR-1, and could be classified as first-generation small molecular activators of FGFR-1 kinase.

THIENOPYRIMIDINE COMPOUNDS

The present invention relates to the use of novel compounds of Formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

METHODS FOR IDENTIFICATION OF JAK KINASE INTERACTING MOLECULES AND FOR THE PURIFICATION OF JAK KINASES

The present invention relates to immobilization compounds and methods useful for the identification of JAK interacting compounds or for the purification or identification of JAK.

PROTEIN KINASE INHIBITORS

Compounds, particularly compounds having spleen tyrosine kinase (Syk) inhibition activity, having the following structure: or a pharmaceutically acceptable salt thereof, wherein R1 is structure (a), (b), (c) or (d): and Ra, Rb, Rc, R2, R3, R4, R5, R6 and R7 are as defined herein. Methods associated with preparation and use of the same, as well as pharmaceutical compositions containing the same, are also disclosed, as well as uses of the same to treat a condition or disorder mediated by a Syk and/or JAK kinase.

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

Inhibition of the vascular endothelial growth factor (VEGF) signaling pathway has emerged as one of the most promising new approaches for cancer therapy. We describe herein the key steps starting from an initial screening hit leading to the discovery of pazopanib, N4-(2,3-dimethyl-2H-indazol- 6-yl)-N4-methyl-N2-(4-methyl-3-sulfonamidophenyl)-2,4- pyrimidinediamine, a potent pan-VEGF receptor (VEGFR) inhibitor under clinical development for renal-cell cancer and other solid tumors.

PHOSPHODIESTERASE 10 INHIBITORS

The present invention if directed to certain cinnoline compounds that are PDE10 inhibitors, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS

The present invention is directed to cinnoline and quinazoline compounds of formula (I) that are PDE10 inhibitors, pharmaceutical compounds containing the same and processes for preparing the same. The invention is also directed to methods of treating diseases mediated by PDE10 enzyme such as obesity, non-insulin dependent diabetes, schizophrenia or bipolar disorder, obsessive-compulsive disorder, and the like.